Next Generation Heart Disease Modeling & Drug Discovery/Screening

Next-Generation Heart Disease Modeling & Drug Discovery/Screening


 Reduce Cost, Cut Time, Improve Efficacy and Safety

Novoheart is a global stem cell biotechnology company dedicated to engineering bioartificial human heart surrogates using state-of-the-art bioengineering approaches.

Numbers you need to know

The impact of what Novoheart has been able to put forward cannot be understated. Our team of scientists is pioneering a new way forward for bioartificial heart tissue and organ modeling. The numbers below trumpet our success.

1st

Genetically Engineered Human Heart Cells

1st

Human

mini-heart

3

Investigational

New Drugs (IND)

25+

Years of experience

in human heart bioengineering

100+

mini-Heart related peer-reviewed publications

12+

Disease Models

Available

Our Products


Evaluating the state of cardiac health requires extensive assessment of a diverse set of functional outputs. Novoheart’s mini-Heart Platform is the ideal solution, consisting of 3 advanced engineered-tissue formats fabricated from human stem cell-derived cardiomyocytes that are designed for assessing specific cardiac functional outputs. Data acquired by the mini-Heart Platform has successfully led to a series of pre-clinical candidates as well as Investigational New Drug (IND) applications and clinical trials.

Learn More Learn More
mini-heart platform

We are changing the course of research and discovery

Save time

Save Time

No Animal Dependency

No Animal Dependency

Unique mini-Heart Platform

Unique mini-Heart Platform

More Cost Effective

More Cost Effective

Representative Disease Models 

HFpEF disease models

Heart Failure with

preserved Ejection Fraction

COVID disease models

COVID

Arrhythmias and Long QT Syndrome disease models

Arrhythmias and

Long QT Syndrome

Friedreich's Ataxia disease models

Friedreich's Ataxia

A Revolution in Human Heart Research

View the video clip for a quick summary of Novoheart’s

game changing mini-Heart Platform.

View our Platform >>
Share by: